This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 28, 2016

Study Completion Date

January 28, 2016

Conditions
PediatricsSolid Tumors
Interventions
DRUG

Eribulin Mesylate

Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.

Trial Locations (18)

1914

Childrens Hospital of Philadelphia, Philadelphia

10032

Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Midwest Children's Cancer Center, Milwaukee

55455

University of Minnesota Cancer Center-Fairview, Minneapolis

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, Houston

92868

Childrens Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

97239

Oregon Health and Science University, Portland

98145

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

Children's Oncology Group

NETWORK

lead

Eisai Inc.

INDUSTRY

NCT02171260 - This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas | Biotech Hunter | Biotech Hunter